On April 18, the California Society of Anesthesiologists had the great pleasure of hosting “Pain Day” – the second day of CSA’s Annual Meeting held this year via a virtual platform. Covid-19 has changed so many things in our day-to-day lives, and one of them is how we interact and communicate. The virtual platform allowed the CSA for the first time, to extend a live interactive conference to members and non-members across the state.
The Sunday Pain Day provided CSA the opportunity to showcase the highly valuable role anesthesiologists play as a consultant to the health system at large. The speakers were from various organizations including but not limited to Sutter, Kaiser, University of Southern California, and several campuses across the University of California. Anesthesiologists, primary care physicians, other subspeciality physicians, administrators and regulators all tuned into the conference to gain insight into the most up to date information regarding pain management.
These timely updates on pain management options relevant to perioperative and Pain Medicine care were not just of benefit to anesthesiologists. The educational opportunities provided by CSA’s Pain Day allowed other California physicians to obtain education required by the Medical Board of California. The MBC require 12 CME on pain management, the treatment of terminally ill and dying patients, and the risks of addiction associated with the use of Schedule II drugs.
One of the highlights of the day was a dynamic discussion with the new Executive Director of the California Medical Board, Bill Prasifka, Deputy Attorney Meghan Anderson from the office of the Attorney General, and Special Agent Brian McGlinchey. The discussion highlighted the role of the Medical Board in the assessing and evaluating problematic opioid prescribing juxtaposed to case law and penalties levied through the Attorney General’s Office.
The day was punctuated by an amazing discussion regarding morphine’s ability to modulate the immune system, followed by ketamine and its novel use for a variety of indications, and the growing role of cannabinoids in pain medicine as a low risk, high yield therapy for pain.
The CSA looks forward to continuing to provide innovative and cutting-edge content as part of our CME offerings – including our three Hawaii Seminars held in summer, fall and winter, as well as our Annual Meeting held each spring, which will hopefully include a reprise of this year’s successful Pain Day. For information on CSA’s world class CME offerings, please visit www.csahq.org/events.
On behalf of CSA’s Education and Programs Division, we extend our gratitude and appreciation to our Program Chairs and our talented presenters.
Dr. David Copenhaver is a board-certified Anesthesiologist and Pain Medicine specialist who serves as Chief of the Division of Pain Medicine in the Department of Anesthesiology and Pain Medicine at UC Davis Health. He is the director of Cancer Pain Management and Supportive Care Program in addition to the Pain Medicine Telehealth program at UC Davis.
Dr. Copenhaver has research interests in health services administration, pain medicine education, responsible opioid management, targeted drug delivery, and the applied use of stem cells in the setting of intervertebral disc disease. He completed his undergraduate degrees in Neuroscience, Physiology and Behavior at UC Davis. He subsequently went on to UCLA to complete his medical school education and a master's degree in public health. Dr. Copenhaver completed his residency in Anesthesiology at Columbia University College of Physicians and Surgeons and his pain medicine fellowship at UC Davis.